Inivata will host a session on liquid biopsy at PMWC January 23rd, 2017
We are excited to be hosting a session on liquid biopsy at the upcoming PMWC conference in Silicon Valley on January 23rd.
Learn more about our session on the Future of ctDNA here: http://www.pmwcintl.com/2…/sessionthemes-clinical-app-ctdna/
This session will include panelists Clive Morris, Inivata CMO; Nitzan Rosenfeld, Inivata CSO; and Ramaswamy Govindan, Director of Medical Oncology at Washington University. You can view a Question & Answer session with our CMO, Clive Morris and PMWC here: http://www.pmwcintl.com/2017sv/clive-morris-qa/
Inivata is a leader in liquid biopsy. Its InVision® platform unlocks essential genomic information from a simple blood draw to guide and personalize cancer treatment, monitor response and detect relapse. Inivata’s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge. Its lead product, InVisionFirst®-Lung is commercially available and offers best-in-class sensitivity and turnaround, providing molecular insights that enable clinicians to make more informed treatment decisions for advanced NSCLC patients. Inivata has also launched the personalized RaDaR™ assay – allowing the highly sensitive detection of residual disease and recurrence. Inivata is partnering with pharmaceutical, biotechnology companies and commercial partners in a range of early and late stage cancer development programs. The Company has a CLIA certified, CAP accredited laboratory in Research Triangle Park, NC and R&D laboratories in Cambridge, UK. For more information, please go to www.inivata.com. Follow us on Twitter @Inivata.